Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.47 |
| ▸ | PPARD | Q03181 | 8/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12740981 | 0.95 | FFAR1 (0.47) | FFAR1PPARDFFAR4GAAMAPK1 | |
| SCHEMBL12736566 | 0.94 | FFAR4 (0.44) | FFAR1PPARDFFAR4GAAMAPK1 | |
| SCHEMBL14766865 | 0.94 | FFAR1 (0.52) | FFAR1PPARDFFAR4MAOBPPARG | |
| SCHEMBL12741006 | 0.91 | FFAR1 (0.47) | FFAR1PPARDFFAR4MAPK1MAOB | |
| SCHEMBL12741016 | 0.91 | FFAR1 (0.43) | FFAR1PPARDFFAR4MAPK1MAOA | |
| SCHEMBL12741014 | 0.90 | FFAR1 (0.49) | FFAR1PPARDFFAR4MAOBPPARG | |
| SCHEMBL12823868 | 0.90 | FFAR1 (0.47) | FFAR1PPARDPPARA | |
| SCHEMBL14767069 | 0.90 | FFAR1 (0.54) | FFAR1PPARDFFAR4MAOBPPARG | |
| SCHEMBL12741007 | 0.89 | FFAR1 (0.46) | FFAR1PPARDFFAR4PPARGPPARA | |
| SCHEMBL12741018 | 0.89 | PTPN11 (0.43) | FFAR1PPARDFFAR4MAPK1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | FFAR1 247/4885PPARD 3762/4885FFAR4 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.